ADC Therapeutics SA (ADCT)

Market Cap	405.79M
Revenue (ttm)	69.56M
Net Income (ttm)	-240.05M
Shares Out	82.81M
EPS (ttm)	-2.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	312,431
Open	4.960
Previous Close	4.730
Day's Range	4.810 - 5.105
52-Week Range	0.360 - 6.040
Beta	1.74
Analysts	Buy
Price Target	7.33 (+49.59%)
Earnings Date	May 6, 2024

About ADCT

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to contin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 15, 2020
• Employees: 273
• Stock Exchange: NYSE
• Ticker Symbol: ADCT

Financial Performance

In 2023, ADCT's revenue was $69.56 million, a decrease of -66.86% compared to the previous year's $209.91 million. Losses were -$240.05 million, 52.8% more than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for ADCT stock is "Buy." The 12-month stock price forecast is $7.33, which is an increase of 49.59% from the latest price.

Price Target

$7.33

(49.59% upside)

Analyst Consensus: Buy